Current Report Filing (8-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 4, 2017

 

PROTO SCRIPT PHARMACEUTICAL CORP.

(Exact name of registrant as specified in charter)

 

Nevada		333-175146		99-0363803
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

9830 6th Street, Suite 103 Rancho Cucamonga, California		91730
(Address of principal executive offices)		(Zip Code)

 

[phone]

Registrant’s telephone number

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

 

Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

 

On October 4, 2017, Proto Script Pharmaceutical Corp. (the “Company”) was notified from its registered public accounting firm (the “Auditor”) that the Auditor had provided the Company with consent to file the Company’s Form 10-K for the fiscal year ended December 31, 2016 which the Company previously filed with the Commission on September 20, 2017, prior to receiving final consent to file by the Auditor’s EQR Partner.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	PROTO SCRIPT PHARMACEUTICAL CORP.
Date: October 19, 2017	By:	/s/ Michelle Rico
		Michelle Rico, President

 

 

3